HSA: APAC’s Regulatory Gold Standard
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first…
Tagged with Bayer
The Long Read / Norway: Unlocking Potential
Equality has long been a deeply held ideal in Norway, where the concept of allemannsretten – the legal right to roam – permeates all aspects of…
Curing the Incurable: Cell & Gene Therapy and A New Age for…
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety. Levy…
Vincent Ruland – Country Division Head, Bayer…
Bayer’s Dr Vincent Ruland highlights his career trajectory from medical doctor to pharma country manager; the company’s priorities in Malaysia,…
Ethics in Artificial Intelligence: Better Prepare Now for New EU…
With upcoming EU regulation poised to have a massive impact on ethical regulations around AI in Europe, Bayer Head of Digital Transformation Saskia…
Bayer Strategy Head: Big Pharma “Needs to Up its Game”
During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing…
Pharmacovigilance: Steadying the Ship Through the COVID-19 Storm
Michael Levy, head of pharmacovigilance at Bayer Pharma and Bayer Consumer Health, makes a compelling case for the critical role of pharmacovigilance…
Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…
Jan Børge Jakobsen – MD, Bayer Norway
Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian…
Axel Steiger – CEO, Bayer Switzerland
Axel Steiger, CEO and CFO for Bayer Switzerland, outlines the importance of the Swiss operations as one of the key global hubs for Bayer, his…
China Pharma News Roundup September 2020
The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and…
New Billion Dollar Pharma Action Fund to Counter ‘Slow…
June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost…
